A total of 618 people participated in the study, led by James LaValle, which was conducted at the Living Longer Clinic in Cincinnati. The clinic tailors "health and vitality assessment" programs for clients.
Between 50 and 70 million Americans suffer from chronic sleep disorders, hindering their ability to function and adversely affecting their health and lifespan, according to a recent National Academy of Sciences report. The findings of the Seditol study suggest the supplement could have implications for the sleepless who prefer to take an all-natural sleep aid over drugs.
Seditol contains extract from Magnolia officinalis and Ziziphus spinosa.
Participants had reported having trouble falling asleep or staying asleep. Ninety-two percent of the subjects reported Seditol helped them relax and 89 percent reported it helped reduce fatigue due to lack of sleep.
The product was administered one hour before bedtime for a minimum of fourteen days.
The patented extract blend works by binding to central nervous system targets associated with drowsiness, including A1 and GABA, claims Next Pharmaceuticals.
The researchers assessed safety with an open-ended question: "Did you dislike anything about Seditol?" Out of the 618 subjects, 576 reported no dislikes (93.2 percent), leaving less than seven percent who reported any dislikes. These complaints included: grogginess in the morning, four percent; headaches, 0.6 percent; sleeplessness, 0.3 percent; bad taste, 0.8 percent; unpleasant dreams, 0.5 percent; light headedness, 0.2 percent; nervousness, 0.2 percent; feeling cold, 0.2 percent.
The subjects were also instructed to contact the clinic in the event of any adverse events or side effects.
Next Pharmaceuticals is a research and development company that markets ingredients including Relora, Nexrutine and Citri-Z to food, beverage, and dietary supplement companies.